Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the breast~  * Metastatic disease~* Meets 1 of the following criteria:~  * Chemotherapy-unresponsive disease defined as 1 of the following:~    * Less than a partial response to 2 consecutive chemotherapy regimens that included an anthracycline and a taxane in combination or succession~   * Progression of disease during or within 3 months of completion of a taxane, anthracycline, or platinol-based regimen~ * Histologically confirmed tumor involvement on bone marrow biopsy~* Measurable or evaluable disease\* defined as the following:~  * Bidimensionally reproducible measurable mass by physical examination, ultrasonography, radiography, CT scan, or MRI~ * Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not fit the criteria for measurability (e.g., ill-defined post-surgical masses or masses assessable in 1 dimension only)~    * Elevation of biological markers (e.g., CA 27.29) is considered evaluable disease NOTE: \*Bone lesions or pleural or peritoneal effusion alone are not considered measurable or evaluable disease~* Appropriate candidate for allogeneic stem cell transplantation~* No active CNS metastases~* Available HLA-identical sibling donor~  * 6/6 antigen match~ * Donor CD34 cells at least 2 times 10\^6/kg recipient weight~* Hormone receptor status:~  * Estrogen receptor negative or positive~    * Estrogen receptor positive tumors must demonstrate progression on at least 1 hormonal manipulation~PATIENT CHARACTERISTICS:~Age~* 18 to 60~Sex~* Female~Menopausal status~* Not specified~Performance status~* Karnofsky 70-100% OR~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC at least 1,500/mm\^3~* Platelet count at least 30,000/mm\^3~Hepatic~* Bilirubin less than 3 times normal\*~* AST and ALT less than 3 times normal\* NOTE: \*Unless abnormality due to malignancy~Renal~* Creatinine no greater than 1.6 mg/dL~Cardiovascular~* LVEF greater than 40% by echocardiography or MUGA~* No myocardial infarction within the past 6 months~Pulmonary~* DLCO greater than 40% of predicted~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No serious localized or systemic infection~* No hypersensitivity to E. coli-derived products~* No history of non-breast malignant disease within the past 5 years except completely excised nonmelanoma skin cancer or carcinoma in situ of the cervix~* No chronic inflammatory disorder requiring concurrent glucocorticosteroids or other immunosuppressive medication~* No psychological condition or social situation that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* No concurrent glucocorticoids~Radiotherapy~* No prior radiotherapy to an indicator lesion unless the lesion shows evidence of progression after discontinuation of the therapy~Surgery~* Not specified~Other~* No concurrent immunosuppressive medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues